Sino Biopharmaceutical (HKG:1177) said a mid-stage trial of its TQA3605 tablets for the treatment of hepatitis B met its primary goal, according to a Hong Kong bourse filing Tuesday.
Results showed the medicine, when combined with antiviral drugs known as nucleos(t)ide analogues, helped kept the disease at bay.
Specifically, after 24 weeks of treatment, HBV-infected adults who received the company's medicine achieved HBV DNA levels below the lower limit of quantification when compared to nucleos(t)ide analogues alone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments